Efficacy and safety data at week 24 from the phase III POSTURE study evaluating oral Apremilast in ankylosing spondylitis


Results of the phase III POSTURE study evaluating Apremilast ( Otezla ), the oral, selective inhibitor of phosphodiesterase 4 ( PDE4 ), in patients with active ankylosing spondylitis. The Apremilast arms did not achieve statistically significant improvement versus the placebo arm for the primary endpoint, the percentage of patients who achieve an ASAS ( Assessment of SpondyloArthritis international Society ) 20 response at week 16. However, in a prespecified analysis, meaningful efficacy was observed at week 24 in a large subset of patients with early-stage disease. Evaluation of the efficacy results is ongoing.

An independent data monitoring committee ( DMC ) has recommended that the study proceed unchanged, based on an assessment of the safety and efficacy data at week 24. According to the protocol, magnetic resonance imaging ( MRI ) data will be collected in a subgroup of subjects at week 52 and at additional time points, and radiographs will be taken on all study patients at week 104 and at additional time points.

The safety and tolerability data observed in the POSTURE study are consistent with previously reported phase II data in ankylosing spondylitis, as well as six phase III studies of Apremilast in psoriatic arthritis or psoriasis. No new safety signals were observed.

POSTURE is a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Apremilast in the treatment of active ankylosing spondylitis.
The primary endpoint of the study is the proportion of subjects in each treatment group who achieve an ASAS ( Assessment of SpondyloArthritis international Society ) 20 response, defined as an improvement for patients of at least 20%, at week 16. Secondary endpoints include other measures of function, disease activity, and quality of life.
In POSTURE, 490 subjects were randomized in a 1:1:1 ratio to receive either Apremilast 20 mg BID ( bis in die ), Apremilast 30 mg BID, or identically-appearing placebo for 24 weeks, with a subsequent long-term extension phase in which all subjects are treated with Apremilast.
The POSTURE study includes adult subjects who have a diagnosis of definite ankylosing spondylitis as defined by the modified New York criteria ( 1984 ); have symptoms of active disease based on a Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) score of greater than or equal to 4; and have a Total Back Pain Numerical Rating Scales ( NRS ) score of greater than or equal to 4.
Subjects can take nonsteroidal anti-inflammatory drug ( NSAID ) therapies, disease-modifying anti-rheumatic drugs ( DMARDs ) or low-dose corticosteroids, as long as they are on a stable dose of these agents prior to baseline and remain on these agents at the same doses through the 24-week placebo-controlled phase.
Subjects must not have prior treatment with a tumor necrosis factor ( TNF ) blocker or any biologic treatment for ankylosing spondylitis. ( Xagena )

Source: Celgene, 2014

XagenaMedicine_2014



Indietro

Altri articoli

Results from two pivotal phase 3 trials evaluating Deucravacitinib, an oral, selective tyrosine kinase 2 ( TYK2 ) inhibitor, for...


The European Commission ( EC ) has granted marketing authorisation for Otezla ( Apremilast ), an oral selective inhibitor of...


Since the publication of the European League Against Rheumatism ( EULAR ) recommendations for the pharmacological treatment of psoriatic arthritis...


New findings on Apremilast ( Otezla ), a selective inhibitor of phosphodiesterase 4 ( PDE4 ), from the ESTEEM 1...


The FDA ( Food and Drug Administration ) has approved Otezla ( Apremilast ), a oral selective inhibitor of...


The Food and Drug Administration ( FDA ) has approved Otezla ( Apremilast ), oral, selective inhibitor of phosphodiesterase 4...


Results from additional efficacy and safety analyses of Apremilast ( Otezla ) from the ESTEEM phase III clinical trial program...


Apremilast ( Otezla ) is an oral small-molecule inhibitor of phosphodiesterase 4 ( PDE4 ) specific for cyclic adenosine monophosphate...


Celgene has announced results of its long-term phase III study on Apremilast, a targeted inhibitor of phosphodiesterase 4 ( PDE4...